These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 25483423)

  • 1. 15 years of ATTEMPTS: a macromolecular drug delivery system based on the CPP-mediated intracellular drug delivery and antibody targeting.
    Ye J; Shin MC; Liang Q; He H; Yang VC
    J Control Release; 2015 May; 205():58-69. PubMed ID: 25483423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ligand-conjugated mesoporous silica nanorattles based on enzyme targeted prodrug delivery system for effective lung cancer therapy.
    Sundarraj S; Thangam R; Sujitha MV; Vimala K; Kannan S
    Toxicol Appl Pharmacol; 2014 Mar; 275(3):232-43. PubMed ID: 24467950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ATTEMPTS system: a macromolecular prodrug strategy for cancer drug delivery.
    Huang Y; Park YS; Wang J; Moon C; Kwon YM; Chung HS; Park YJ; Yang VC
    Curr Pharm Des; 2010 Jul; 16(21):2369-76. PubMed ID: 20618157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PTD-Modified ATTEMPTS for Enhanced Toxin-based Cancer Therapy: An In Vivo Proof-of-Concept Study.
    Shin MC; Zhang J; Min KA; He H; David AE; Huang Y; Yang VC
    Pharm Res; 2015 Aug; 32(8):2690-703. PubMed ID: 25701313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased tumor targeted delivery using a multistage liposome system functionalized with RGD, TAT and cleavable PEG.
    Mei L; Fu L; Shi K; Zhang Q; Liu Y; Tang J; Gao H; Zhang Z; He Q
    Int J Pharm; 2014 Jul; 468(1-2):26-38. PubMed ID: 24709209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. pH-Sensitive nanoparticles as smart carriers for selective intracellular drug delivery to tumor.
    Li XX; Chen J; Shen JM; Zhuang R; Zhang SQ; Zhu ZY; Ma JB
    Int J Pharm; 2018 Jul; 545(1-2):274-285. PubMed ID: 29733971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction and characterization of a t-PA mutant for use in ATTEMPTS: a drug delivery system for achieving targeted thrombolysis.
    Yang VC; Naik SS; Song H; Dombkowski AA; Crippen G; Liang JF
    J Control Release; 2005 Dec; 110(1):164-76. PubMed ID: 16260060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ATTEMPTS: a heparin/protamine-based triggered release system for the delivery of enzyme drugs without associated side-effects.
    Park YJ; Liang JF; Song H; Li YT; Naik S; Yang VC
    Adv Drug Deliv Rev; 2003 Feb; 55(2):251-65. PubMed ID: 12564979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracellular delivery of nanoparticles with CPPs.
    Sawant R; Torchilin V
    Methods Mol Biol; 2011; 683():431-51. PubMed ID: 21053148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of antibody targeting and PTD-mediated intracellular toxin delivery for colorectal cancer therapy.
    Shin MC; Zhang J; Ah Min K; Lee K; Moon C; Balthasar JP; Yang VC
    J Control Release; 2014 Nov; 194():197-210. PubMed ID: 25204286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ATTEMPTS delivery systems for macromolecular drugs.
    Kwon YM; Li Y; Naik S; Liang JF; Huang Y; Park YJ; Yang VC
    Expert Opin Drug Deliv; 2008 Nov; 5(11):1255-66. PubMed ID: 18976135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PTD-modified ATTEMPTS system for enhanced asparaginase therapy: a proof-of-concept investigation.
    Kwon YM; Li YT; Liang JF; Park YJ; Chang LC; Yang VC
    J Control Release; 2008 Sep; 130(3):252-8. PubMed ID: 18652856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heparin-Regulated Prodrug-Type Macromolecular Theranostic Systems for Cancer Therapy.
    Wang H; Moon C; Shin MC; Wang Y; He H; Yang VC; Huang Y
    Nanotheranostics; 2017; 1(1):114-130. PubMed ID: 29071181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controlled release of free doxorubicin from peptide-drug conjugates by drug loading.
    Chen Z; Zhang P; Cheetham AG; Moon JH; Moxley JW; Lin YA; Cui H
    J Control Release; 2014 Oct; 191():123-30. PubMed ID: 24892976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic co-delivery of doxorubicin and paclitaxel using multi-functional micelles for cancer treatment.
    Duong HH; Yung LY
    Int J Pharm; 2013 Sep; 454(1):486-95. PubMed ID: 23792465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ATTEMPTS: a heparin/protamine-based prodrug approach for delivery of thrombolytic drugs.
    Liang JF; Park YJ; Song H; Li YT; Yang VC
    J Control Release; 2001 May; 72(1-3):145-56. PubMed ID: 11389993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved Protein Toxin Delivery Based on ATTEMPTS Systems.
    Chen Y; Zhang M; Min KA; Wang H; Shin MC; Li F; Yang VC; Huang Y
    Curr Drug Targets; 2018 Feb; 19(4):380-392. PubMed ID: 28260497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzyme-triggered, cell penetrating peptide-mediated delivery of anti-tumor agents.
    He H; Sun L; Ye J; Liu E; Chen S; Liang Q; Shin MC; Yang VC
    J Control Release; 2016 Oct; 240():67-76. PubMed ID: 26514292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Magnetic polycarbonate microspheres for tumor-targeted delivery of tumor necrosis factor.
    Hu B; Du HJ; Yan GP; Zhuo RX; Wu Y; Fan CL
    Drug Deliv; 2014 May; 21(3):204-12. PubMed ID: 24117028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ATTEMPTS: a heparin/protamine-based delivery system for enzyme drugs.
    Liang JF; Li YT; Song H; Park YJ; Naik SS; Yang VC
    J Control Release; 2002 Jan; 78(1-3):67-79. PubMed ID: 11772450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.